Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Research & Development (2020 - 2025)

Tarsus Pharmaceuticals has reported Research & Development over the past 6 years, most recently at $18.0 million for Q4 2025.

  • Quarterly results put Research & Development at $18.0 million for Q4 2025, up 6.89% from a year ago — trailing twelve months through Dec 2025 was $64.3 million (up 20.48% YoY), and the annual figure for FY2025 was $64.3 million, up 20.48%.
  • Research & Development for Q4 2025 was $18.0 million at Tarsus Pharmaceuticals, up from $16.3 million in the prior quarter.
  • Over the last five years, Research & Development for TARS hit a ceiling of $18.0 million in Q4 2025 and a floor of $500000.0 in Q4 2022.
  • Median Research & Development over the past 5 years was $12.2 million (2024), compared with a mean of $11.7 million.
  • Biggest five-year swings in Research & Development: crashed 93.78% in 2022 and later surged 2561.0% in 2023.
  • Tarsus Pharmaceuticals' Research & Development stood at $8.0 million in 2021, then crashed by 93.78% to $500000.0 in 2022, then surged by 2561.0% to $13.3 million in 2023, then grew by 26.82% to $16.9 million in 2024, then grew by 6.89% to $18.0 million in 2025.
  • The last three reported values for Research & Development were $18.0 million (Q4 2025), $16.3 million (Q3 2025), and $15.6 million (Q2 2025) per Business Quant data.